After analyzing individual members, the TFAP2A gene was altered in 2% of all NSCLC patients, in LUAD modifications in this gene sequence constitute 2% of cases, the most common of which are mutations and amplifications. This evidence concerns the gene TFAP2A and non-small cell lung carcinoma.